{
    "clinical_study": {
        "@rank": "154632", 
        "arm_group": [
            {
                "arm_group_label": "azilsartan medoximil.", 
                "arm_group_type": "Active Comparator", 
                "description": "Subjects randomized to azilsartan medoximil arm will take 80 mg of azilsartan medoximil tablets by mouth each day."
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Subjects randomized to the placebo arm will take 80 mg of placebo tablets by mouth each day"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of the research is to evaluate the effect of azilsartan medoximil on blood\n      pressure and urinary aldosterone levels in postmenopausal females."
        }, 
        "brief_title": "Effect of Azilsartan on Aldosterone in Postmenopausal Females", 
        "completion_date": {
            "#text": "January 2018", 
            "@type": "Anticipated"
        }, 
        "condition": "Hypertension", 
        "condition_browse": {
            "mesh_term": "Hypertension"
        }, 
        "detailed_description": {
            "textblock": "The study is a randomized, placebo-controlled trial of 40 post-menopausal females with stage\n      1 hypertension"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Female\n\n          -  Ages 45-70\n\n          -  Post-menopause: have not had a menstrual period for one year or more\n\n          -  Diagnosed with Stage 1 hypertension\n\n          -  Body Mass Index (BMI) greater than or equal to 28\n\n        Exclusion Criteria:\n\n          -  Male\n\n          -  Diagnosed with Stage 2 hypertension\n\n          -  Stage 1 hypertension requiring more than one agent\n\n          -  Pregnancy or attempting pregnancy\n\n          -  Use of oral contraceptive pills\n\n          -  Use of hormone replacement therapy\n\n          -  Use of steroids\n\n          -  Stage 3 or greater kidney disease\n\n          -  Diabetes mellitus\n\n          -  untreated hypothyroidism or hyperthyroidism\n\n          -  primary hyperaldosteronism\n\n          -  Cushing's disease\n\n          -  obstructive sleep apnea\n\n          -  chronic illness, e.g. chronic liver disease\n\n          -  NYHA class III or greater heart failure\n\n          -  moderate to severe lung disease"
            }, 
            "gender": "Female", 
            "healthy_volunteers": "No", 
            "maximum_age": "70 Years", 
            "minimum_age": "45 Years"
        }, 
        "enrollment": {
            "#text": "40", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "January 22, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01774591", 
            "org_study_id": "12-1179"
        }, 
        "intervention": [
            {
                "arm_group_label": "azilsartan medoximil.", 
                "intervention_name": "Azilsartan medoximil", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Placebo", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Post Menopause", 
            "Female", 
            "Obese"
        ], 
        "lastchanged_date": "September 6, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Chicago", 
                    "country": "United States", 
                    "state": "Illinois", 
                    "zip": "60637"
                }, 
                "name": "University of Chicago"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "Effect of Azilsartan on Aldosterone in Postmenopausal Females", 
        "overall_contact": {
            "email": "cschalff@medicine.bsd.uchicago.edu", 
            "last_name": "Carrie Schlaffer", 
            "phone": "773-702-2591"
        }, 
        "overall_official": {
            "affiliation": "University of Chicago", 
            "last_name": "George Bakris, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Institutional Review Board", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "January 2018", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "To evaluate the effect of an angiotensin receptor blocker (azilsartan medoximil) on blood pressure in postmenopausal females.", 
            "safety_issue": "No", 
            "time_frame": "26 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01774591"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "measure": "To evaluate the effect of an angiotensin receptor blocker (azilsartan medoximil) on urinary aldosterone levels in postmenopausal females.", 
            "safety_issue": "No", 
            "time_frame": "26 weeks"
        }, 
        "source": "University of Chicago", 
        "sponsors": {
            "collaborator": {
                "agency": "Takeda", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "University of Chicago", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "January 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "January 2013"
    }
}